News

DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024

9 Read more
DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
Read more
12 May 2023
Ad hoc announcement pursuant to Art. 53 LR
DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
Read more
Read more
11 May 2023
Corporate news
New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)
Read more
Read more
04 May 2023
Corporate news
Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)
Read more
Read more
04 May 2023
Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group has successfully completed the sale of its Swiss business to Migros
Read more
Read more
20 Apr 2023
Corporate news
Zur Rose Group: Revenue in the first quarter 2023 in line with plan
Read more
Read more
12 Apr 2023
Corporate news
Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023
Read more
Read more
23 Mar 2023
Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group: Revenue and earnings targets for 2022 achieved; significant step towards profitability
Read more
Read more
03 Feb 2023
Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany
Read more
Read more
03 Feb 2023
Corporate news
Zur Rose Switzerland to become part of Medbase Group
Read more

Annual Online Report 2022

DocMorris informs about the latest developments and shares multimedia insights into various business areas.

9 Read more
Annual Online Report 2022
  • All news
  • Ad hoc news
  • Corporate news

26 May 2023 Ad hoc announcement pursuant to Art. 53 LR
DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
Read more

12 May 2023 Ad hoc announcement pursuant to Art. 53 LR
DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024
Read more

11 May 2023 Corporate news
New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)
Read more

04 May 2023 Corporate news
Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)
Read more

04 May 2023 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group has successfully completed the sale of its Swiss business to Migros
Read more

20 Apr 2023 Corporate news
Zur Rose Group: Revenue in the first quarter 2023 in line with plan
Read more

12 Apr 2023 Corporate news
Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023
Read more

23 Mar 2023 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group: Revenue and earnings targets for 2022 achieved; significant step towards profitability
Read more

03 Feb 2023 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany
Read more

03 Feb 2023 Corporate news
Zur Rose Switzerland to become part of Medbase Group
Read more
Zur Rose Group: Revenue target 2022 achieved, EBITDA better than expected
19 Jan 2023 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group: Revenue target 2022 achieved, EBITDA better than expected
Read more

24 Nov 2022 Corporate news
Zur Rose Group takes next step towards profitability and further reduces complexity in Germany
Read more

01 Nov 2022 Ad hoc announcement pursuant to Art. 53 LR
Procurement and supply chain brought together under the new Chief Operations Officer
Read more

20 Oct 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group announces results of Tender Offer
Read more
After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022
20 Oct 2022 Corporate news
After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022
Read more

07 Oct 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group announces preliminary result and extension of Tender Offer
Read more

23 Sep 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group announces a tender offer for all of its CHF 115 million outstanding bonds due 2023
Read more

13 Sep 2022 Corporate news
Final allocations of Zur Rose approx. CHF 95 million Convertible Bonds Offering
Read more

01 Sep 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process
Read more

31 Aug 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process
Read more
Zur Rose Group speeds up path to profitability and plans break-even at EBITDA level in 2023
18 Aug 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group speeds up path to profitability and plans break-even at EBITDA level in 2023
Read more

22 Jun 2022 Corporate news
Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
Read more

31 May 2022 Corporate news
Betül Susamis Unaran leaves Zur Rose Group
Read more

28 Apr 2022 Corporate news
Zur Rose Group AG: Shareholders approve all proposals
Read more

20 Apr 2022 Corporate news
Zur Rose Group sees revenue perform as expected in the first quarter of 2022
Read more

06 Apr 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group AG publishes invitation to the Annual General Meeting of 28 April 2022
Read more

24 Mar 2022 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued
Read more

20 Jan 2022 Corporate news
Zur Rose Group: steady growth in a volatile market environment
Read more

10 Jan 2022 Corporate news
Zur Rose Group nominates Rongrong Hu as director
Read more

16 Dec 2021 Corporate news
Zur Rose and the Swiss Association for the Blind and Visually Impaired make it easier for people with a visual impairment to take medication
Read more

09 Dec 2021 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group successfully completed capital increase from authorised capital and sets placement price at CHF 290 per new share
Read more

08 Dec 2021 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group decides on capital increase from authorised capital and starts accelerated bookbuilding to make full use of increasing market opportunities
Read more

26 Nov 2021 Corporate news
eHealth-Tec achieves first place in the TOP 100 competition
Read more

28 Oct 2021 Corporate news
Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes
Read more

21 Oct 2021 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group: Board of Directors nominates Walter Oberhänsli as Chairman and appoints Walter Hess as new CEO
Read more

21 Oct 2021 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group continues to grow strongly
Read more

24 Aug 2021 Corporate news
Health app Well heralds the future of healthcare
Read more

18 Aug 2021 Ad hoc announcement pursuant to Art. 53 LR
Zur Rose Group accelerates growth in second quarter with revenue up 26 per cent
Read more

09 Jul 2021 Corporate news
No more paper: e-prescriptions are coming
Read more

28 May 2021 Corporate news
Faster and more secure access to the gematik e-prescription with eHealth-Tec: Compatible software development kit for software providers
Read more

29 Apr 2021 Corporate news
Annual General Meeting of Zur Rose Group AG: Shareholders approve all proposals
Read more

29 Apr 2021 Corporate news
DocMorris expands management team: Dr. Ulrich Thomé is appointed Chief Strategy Officer
Read more

20 Apr 2021 Corporate news
Zur Rose Group signals dynamic revenue development in the first quarter of 2021
Read more

07 Apr 2021 Corporate news
Zur Rose Group AG publishes invitation to the Annual General Meeting on 29 April 2021
Read more

31 Mar 2021 Corporate news
Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life.
Read more

18 Mar 2021 Corporate news
Zur Rose Group further extends European market leadership and successfully implements healthcare platform
Read more

11 Feb 2021 Corporate news
DocMorris goes European: new branding for marketplaces in Spain and France
Read more

21 Jan 2021 Corporate news
The Zur Rose Group accelerates growth
Read more

13 Jan 2021 Corporate news
Zur Rose vindicated after court finds CEO Walter Oberhänsli not guilty
Read more

11 Jan 2021 Corporate news
Collaboration between Zur Rose Group and Novo Nordisk: The Zur Rose Group and Novo Nordisk combine their expertise to improve the health journeys of people with obesity
Read more
Load more